| Code | CSB-RA011587MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to Ustekinumab-hmny, targeting IL12B (interleukin-12 subunit beta), also known as the p40 subunit. IL12B is a shared component of both interleukin-12 and interleukin-23, two critical cytokines involved in inflammatory and immune responses. IL-12 promotes Th1 cell differentiation and IFN-γ production, while IL-23 supports Th17 cell maintenance and IL-17 production. Dysregulation of IL12B-containing cytokines is implicated in various autoimmune and inflammatory conditions, including psoriasis, psoriatic arthritis, Crohn's disease, and inflammatory bowel disease.
Ustekinumab-hmny is a human monoclonal antibody that binds specifically to the p40 subunit, thereby neutralizing the biological activity of both IL-12 and IL-23. This biosimilar antibody serves as a valuable research tool for investigating IL12B-mediated signaling pathways, studying cytokine networks in immune regulation, and exploring therapeutic mechanisms in inflammatory disease models. It enables researchers to examine the roles of IL-12 and IL-23 in various experimental contexts and disease states.
There are currently no reviews for this product.